On the basis of our unique APIs, we offer our marketing partners a one-stop-shop solution for worry-free generic finished dosage forms (FDF). We offer worldwide out-licensing of our proprietary dossiers and can provide full supply solution for all of our FDFs.
Founded in 1869, Centrient looks back at over 140 years of innovation, from fermentation and microbiology in the late 1800s, over penicillin production development in the 1940s, the enzymatic revolution in antibiotic production in the 2000s, the first enzymatic statin, to new state-of-the-art formulations for generic pharmaceuticals today.
We have the advantage of using our own high quality APIs, the PureActives®, in our beta-lactam and statin products, which deliver unique quality and performance in our finished dosage formulations.
What sets Centrient Pharmaceuticals apart is that we are a pure business-to-business provider of generic finished dosage forms, not marketing the products ourselves and therefore not competing with our customers in the end market. All our dossiers are ready available for out-licensing to our partners world-wide.
European-based production facilities and supply chain
We work primarily with European-based finished dosage forms manufacturers. Customers can be confident that the origin, traceability and quality of our products are impeccable.
Proactive QA, RA and artwork services
With our extensive regulatory and quality assurance know-how and services, doing business with us enables you to focus on what truly counts: your business and your customers.
Reliable supply chain via backward integration
We provide intermediates, active pharmaceutical ingredients (APIs) and finished dosage forms based on our backward integrated global manufacturing capabilities. As a member of the Pharmaceutical Supply Chain Initiative, we ensure our supply chain is of the highest standards.
Leading the way in responsible production
We operate dedicated wastewater treatments plants 24/7/365 at our manufacturing sites and apply antimicrobial activity testing to ensure disposed water is clean.
PureActives® – the enzymatic difference
Our patented enzymatic platform completely replaces the traditional 13-step antibiotic production process with natural processes that eliminate the use of solvents or other chemicals. As well, the majority of the chemical steps in producing our statins have been replaced with enzymatic processes.
Our Out-licensing Portfolio*
Capsules, hard (EU-CTD)
(Dispersible) Tablets (EU-CTD)
Powder for oral suspension (EU-CTD)
Amoxicillin + clavulanic acid
Film-coated tablets (FCT) (EU-CTD)
Powder for oral suspension (POS) (EU-CTD)
Powder for oral suspension in sachet (SAC) (EU-CTD)
Atorvastatin Film-coated tablets (FCT) (EU-CTD)
Rosuvastatin Film-coated tablets (FCT) (EU-CTD)
Caspofungin Powder for concentrate for solution for infusion (PSI) (EU-CTD)
*All our dossiers are ready available for worldwide filings dependent on local regulatory requirements.
Product fact sheets for our products are available upon request.